Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays

Documenti analoghi

• Response to Letter to the Editor regarding “Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays”
  di: Michael L. Garelja, et al.
  Pubblicazione: (2026)
• Response to: Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays
  di: Alicia Alpuente, et al.
  Pubblicazione: (2026)
• Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists
  di: Zoe Tasma, et al.
  Pubblicazione: (2025)
• Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update
  di: Andrew C. Charles, et al.
  Pubblicazione: (2024)
• Comment on “Plasma calcitonin gene‐related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion”
  di: Gabriel Gárate, et al.
  Pubblicazione: (2024)